Scope Fluidics plans to move to WSE’s regulated market n 2021
19:00
NewConnect-listed biotechnology company, Scope Fluidics, which develops innovative projects in the field of medical diagnostics, has decided to transfer the company
from the NewConnect market to the regulated market of the WSE. The dynamic development of the company and flexible securing of project financing from the EIB are conducive to the company's listing on the regulated market of the Warsaw Stock Exchange.
“Development of projects and our entire company, favorable forecasts for the molecular diagnostics market, and the growing market value of Scope Fluidics allow us to seriously think about transferring quotations to the regulated market of the Warsaw Stock Exchange. In this way, we want to increase our recognition and open up to a wider group of investors, including global ones. I also believe that the presence among the largest companies listed on the Polish stock exchange will strengthen our position in the med-tech market. It is also a step in line with Scope Fluidics' long-term development plans - i.e. working on two or three projects in parallel,” Szymon Ruta, Member of the Management Board and Financial Director of Scope Fluidics, said.
Scope Fluidics plans to change the quotation market in 2021. Currently, the company will begin analyzes aimed at identifying the optimal date, scenarios and conditions under which the company's shares would be introduced to the regulated market of the WSE.
(WBJ)
